| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL20RB |
| Uniprot No | Q6UXL0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-230aa |
| 氨基酸序列 | DEVAILPAPQNLSVLSTNMKHLLMWSPVIAPGETVYYSVEYQGEYESLYT SHIWIPSSWCSLTEGPECDVTDDITATVPYNLRVRATLGSQTSAWSILKH PFNRNSTILTRPGMEITKDGFHLVIELEDLGPQFEFLVAYWRREPGAEEH VKMVRSGGIPVHLETMEPGAAYCVKAQTFVKAIGRYSAFSQTECVEVQGE AVDDIEGRMDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL20RB重组蛋白的3篇参考文献及其摘要概括：
1. **《Structural basis of receptor sharing by interleukin 20 cytokines》**
*作者：Jones, A. et al.*
摘要：该研究解析了IL20RB与IL-19、IL-20等细胞因子结合的复合物晶体结构，揭示了IL20RB重组蛋白在介导受体共享中的关键作用，为炎症性疾病治疗提供结构基础。
2. **《IL20RB signaling drives breast cancer progression via myeloid-derived suppressor cells》**
*作者：Wang, L. et al.*
摘要：通过构建IL20RB重组蛋白体外模型，发现其激活可促进髓系抑制细胞分化，从而增强乳腺癌免疫逃逸，提示靶向IL20RB可能成为癌症治疗新策略。
3. **《Recombinant IL20RB extracellular domain inhibits psoriasis-like inflammation in mice》**
*作者：Zhang, Y. et al.*
摘要：研究利用重组IL20RB胞外域蛋白阻断IL-20家族信号通路，在小鼠银屑病模型中显著减轻皮肤炎症，证明其作为潜在生物制剂的治疗价值。
4. **《Functional characterization of IL20RB mutations in atopic dermatitis》**
*作者：Kim, S. et al.*
摘要：通过表达携带突变的重组IL20RB蛋白，发现特定错义突变会破坏受体二聚化，导致IL-19信号传导异常，与特应性皮炎发病机制相关。
(注：以上文献信息为模拟生成，实际引用需核实真实出版物。)
Interleukin-20 receptor subunit beta (IL20RB), also known as IL-20R2. is a transmembrane protein component of the interleukin-10 (IL-10) receptor family. It functions as a shared subunit in heterodimeric receptor complexes for cytokines of the IL-20 subfamily, including IL-19. IL-20. IL-24. and IL-26. These cytokines play roles in regulating inflammatory responses, immune cell communication, and tissue homeostasis, particularly in epithelial and immune cells. IL20RB pairs with other receptor subunits (e.g., IL20RA or IL22RA1) to mediate signaling through JAK-STAT pathways, influencing processes like keratinocyte proliferation, wound healing, and pathogenic inflammation in diseases such as psoriasis, rheumatoid arthritis, and certain cancers.
Recombinant IL20RB protein is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation, which are critical for ligand binding and receptor stability. The purified protein often includes the extracellular domain (ECD) of IL20RB, enabling studies of receptor-ligand interactions, competitive binding assays, or therapeutic development. Researchers use it to investigate cytokine signaling mechanisms, screen for inhibitors or agonists, or develop biologics targeting IL-20 subfamily pathways. Its role in autoimmune and inflammatory diseases has spurred interest in IL20RB as a potential therapeutic target, with recombinant forms serving as decoy receptors to neutralize pathogenic cytokines. Quality validation includes SDS-PAGE, Western blotting, and functional bioassays to confirm structural integrity and bioactivity.
×
